Analytic Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Analytic Investors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,142	Closed	-$736K	–	548
2015 Q2	$736K	Buy	+6,142	New	+$734K	0.01%	414
2014 Q1	–	Sell	-6,634	Closed	-$427K	–	551
2013 Q4	$427K	Buy	+6,634	New	+$396K	0.01%	399

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Analytic Investors's ALNY Position: Q3 2015 in Review

Analytic Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 6,142 shares — an estimated $736K sold.

Analytic Investors first reported a position in ALNY in Q4 2013 and held it in 2 quarters. The position peaked at $736K in Q2 2015. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

Analytic Investors reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Analytic Investors sold 6,142 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $736K.
Analytic Investors first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 2 quarters.
Analytic Investors's Alnylam Pharmaceuticals position peaked at $736K in Q2 2015.
258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on Analytic Investors's 13F filing for Q3 2015, filed 12 Nov 2015.